<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="148005">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01930487</url>
  </required_header>
  <id_info>
    <org_study_id>007</org_study_id>
    <nct_id>NCT01930487</nct_id>
  </id_info>
  <brief_title>The Effects of an Antioxidant Formulation on Ocular Blood Flow</brief_title>
  <official_title>The Effects of an Antioxidant Formulation on Intraocular Pressure, Ocular Perfusion Pressure, Retrobulbar, Retinal Capillary and Choroidal Blood Flow</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ScienceBased Health</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ScienceBased Health</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to evaluate the effects of an antioxidant formula versus placebo on ocular
      blood flow in a randomized double-blind, crossover design.

      Based upon preliminary data, it is hypothesized that a dietary supplement containing a
      variety of ingredients with antioxidant properties will, compared to placebo, increase
      ocular perfusion pressure, retrobulbar, retinal capillary and choroidal blood flow, and
      maintain these effects over the course of the treatment period.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>retinal capillary blood flow</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>retinal capillary blood flow in arbitrary units.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retrobulbar blood flow velocities and vascular resistance</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Central retinal artery, ophthalmic artery, and temporal and nasal short posterior artery:  peak systolic and end diastolic blood flow velocities (cm/s) and vascular resistance (ratio).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ocular perfusion pressure</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>2/3 Mean arterial pressure - intraocular pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular pulse amplitude</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>an measure used to estimate choroid blood flow in bulk</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>dietary supplement with antioxidants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dietary supplement with antioxidants, Ginkgo biloba, Bilberry extract</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo identical in appearance to active</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>dietary supplement with antioxidants</intervention_name>
    <description>Formulation contains vitamins, a mineral, dietary antioxidants, amino acids, polyphenols and polyunsaturated fatty acids</description>
    <arm_group_label>dietary supplement with antioxidants</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Optic Nerve Formula</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo
Softgels manufactured to mimic the appearance of active, dietary supplement with antioxidants</description>
    <arm_group_label>dietary supplement with antioxidants</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 30 years or older.

          -  Confirmed diagnosis of open angle glaucoma by glaucoma specialist in the study eye,
             as evidenced from criteria representative of glaucomatous optic nerve damage such as
             specific optic disc or retinal nerve fiber layer structural abnormalities and/or
             visual field abnormalities.

          -  Best corrected visual acuity at 20/60 or better in study eye.

          -  Willingness to avoid caffeine and smoking for 12 hours before and during the study
             visits.

        Exclusion Criteria:

          -  History of acute angle-closure or a narrow, occluding of anterior chamber angle by
             gonioscopy.

          -  History of chronic or recurrent inflammatory eye diseases or signs of intraocular
             trauma and/or unreliable applanation tonometry.

          -  Severe, unstable or uncontrolled cardiovascular, renal or pulmonary disease

          -  History of/or current renal or hepatic impairment.

          -  History of/or current bronchial asthma, severe chronic obstructive pulmonary disease,
             sinus bradycardia, second or third degree atrioventricular block, or cardiogenic
             shock.

          -  Recent surgery or surgery planned near study timeline

          -  History of bleeding disorder

          -  Use of blood thinning medications

          -  Use of specified dietary supplements for three weeks prior to study entry and
             throughout study period.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alon Harris, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Ophthalmology, Professor of Cellular and Integrative Physiology, Director Clinical Research Glick Eye Institute, Indiana University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brent A. Siesky, PhD</last_name>
    <phone>317-278-0177</phone>
    <email>bsiesky@indiana.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alon Harris, PhD</last_name>
    <phone>317-278-0177</phone>
    <email>alharris@indiana.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Glick Eye Institute, Ocular Vascular Research Center, Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brent A Siesky, PhD</last_name>
      <phone>317-278-0177</phone>
      <email>bsiesky@indiana.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 23, 2013</lastchanged_date>
  <firstreceived_date>August 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary open angle glaucoma</keyword>
  <keyword>intraocular pressure</keyword>
  <keyword>ocular perfusion pressure</keyword>
  <keyword>retrobulbar blood flow</keyword>
  <keyword>retinal capillary blood flow</keyword>
  <keyword>choroidal blood flow</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antioxidants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
